secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0001493152-24-020832
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity guides Q4 2023 revenue ~$12.1M, Q1 2024 revenue ~$14.8M
------------------------------------------------------------------

- Preliminary Q4 2023 net revenue ~$12.1M from biomaterial product sales and biobanking services.
- Preliminary Q1 2024 net revenue ~$14.8M from the same segments, up ~22% sequentially.
- Full-year 2023 and Q1 2024 financials not yet finalized; subject to audit/review adjustments.
- Company hosted an Investor & R&D Day on May 21, 2024, with presentation posted on IR website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224020832/0001493152-24-020832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224020832/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer